Wave Life Sciences Enters Material Definitive Agreement
Ticker: WVE · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1631574
| Field | Detail |
|---|---|
| Company | Wave Life Sciences Ltd. (WVE) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0, $19.00, $18.9999, $0.0001, $402.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, regulation-fd, filing
TL;DR
Wave Life Sciences signed a big deal on 12/9/25. Details in new 8-K.
AI Summary
Wave Life Sciences Ltd. announced on December 9, 2025, that it entered into a material definitive agreement. The company also disclosed information related to Regulation FD and other events, along with financial statements and exhibits. The filing was made on December 11, 2025.
Why It Matters
This filing indicates a significant new contract or partnership for Wave Life Sciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can carry significant risks depending on the nature of the agreement, which is not fully detailed in this initial filing.
Key Players & Entities
- Wave Life Sciences Ltd. (company) — Registrant
- December 9, 2025 (date) — Earliest event reported
- December 11, 2025 (date) — Filing date
FAQ
What is the nature of the material definitive agreement entered into by Wave Life Sciences?
The filing states that Wave Life Sciences Ltd. entered into a material definitive agreement on December 9, 2025, but the specific details of this agreement are not provided in the summary information.
What other items are disclosed in this 8-K filing?
In addition to the material definitive agreement, the filing includes disclosures related to Regulation FD, other events, and financial statements and exhibits.
When was this 8-K report filed with the SEC?
This 8-K report was filed with the SEC on December 11, 2025.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Wave Life Sciences Ltd.
What is the Commission File Number for Wave Life Sciences Ltd.?
The Commission File Number for Wave Life Sciences Ltd. is 001-37627.
Filing Stats: 1,374 words · 5 min read · ~5 pages · Grade level 11.1 · Accepted 2025-12-10 21:47:49
Key Financial Figures
- $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
- $19.00 — Shares"), at a public offering price of $19.00 per Share (as defined below), and, in l
- $18.9999 — ry shares at a public offering price of $18.9999 per Pre-Funded Warrant, which represent
- $0.0001 — offering price for the Shares less the $0.0001 per share exercise price for each Pre-F
- $402.5 million — fering are expected to be approximately $402.5 million before deducting underwriting discounts
Filing Documents
- d88507d8k.htm (8-K) — 35KB
- d88507dex11.htm (EX-1.1) — 334KB
- d88507dex41.htm (EX-4.1) — 66KB
- d88507dex51.htm (EX-5.1) — 57KB
- d88507dex52.htm (EX-5.2) — 15KB
- d88507dex991.htm (EX-99.1) — 11KB
- g88507g1210134622070.jpg (GRAPHIC) — 3KB
- g88507g1210134900623.jpg (GRAPHIC) — 3KB
- g88507g23e89.jpg (GRAPHIC) — 4KB
- g88507g60c53.jpg (GRAPHIC) — 2KB
- g88507g79d11.jpg (GRAPHIC) — 3KB
- 0001193125-25-314746.txt ( ) — 784KB
- wve-20251209.xsd (EX-101.SCH) — 3KB
- wve-20251209_lab.xml (EX-101.LAB) — 18KB
- wve-20251209_pre.xml (EX-101.PRE) — 11KB
- d88507d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d)Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated December 9, 2025, by and between the Company and Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of WongPartnership LLP. 5.2 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 99.1 Press Release of Wave Life Sciences Ltd., dated December 9, 2025, announcing the pricing of the underwritten offering. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Paul B. Bolno, M.D. Paul B. Bolno, M.D. President and Chief Executive Officer Date: December 10, 2025